WO1996006860A2 - Gradual modification, super-agonists and antagonists of signal-proteins and peptides - Google Patents
Gradual modification, super-agonists and antagonists of signal-proteins and peptides Download PDFInfo
- Publication number
- WO1996006860A2 WO1996006860A2 PCT/NL1995/000292 NL9500292W WO9606860A2 WO 1996006860 A2 WO1996006860 A2 WO 1996006860A2 NL 9500292 W NL9500292 W NL 9500292W WO 9606860 A2 WO9606860 A2 WO 9606860A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- modification
- substance
- activity
- residues
- combination
- Prior art date
Links
- 230000004048 modification Effects 0.000 title claims abstract description 81
- 238000012986 modification Methods 0.000 title claims abstract description 81
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 32
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 16
- 239000005557 antagonist Substances 0.000 title abstract description 17
- 230000002483 superagonistic effect Effects 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 55
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 46
- 239000000126 substance Substances 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 34
- 238000007385 chemical modification Methods 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 230000004071 biological effect Effects 0.000 claims abstract description 25
- 230000004807 localization Effects 0.000 claims abstract description 18
- 108091005804 Peptidases Proteins 0.000 claims abstract description 16
- 239000004365 Protease Substances 0.000 claims abstract description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract description 16
- 230000003197 catalytic effect Effects 0.000 claims abstract description 16
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 12
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 10
- 230000008859 change Effects 0.000 claims abstract description 9
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims abstract description 8
- 230000004572 zinc-binding Effects 0.000 claims abstract description 8
- 230000029936 alkylation Effects 0.000 claims abstract description 6
- 238000005804 alkylation reaction Methods 0.000 claims abstract description 6
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 51
- 102000000646 Interleukin-3 Human genes 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 45
- 239000003102 growth factor Substances 0.000 claims description 23
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 21
- 230000027455 binding Effects 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 102000005962 receptors Human genes 0.000 claims description 15
- 108020003175 receptors Proteins 0.000 claims description 15
- 230000001629 suppression Effects 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 13
- 238000001962 electrophoresis Methods 0.000 claims description 12
- 238000004989 laser desorption mass spectroscopy Methods 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 9
- 102000006335 Phosphate-Binding Proteins Human genes 0.000 claims description 7
- 108010058514 Phosphate-Binding Proteins Proteins 0.000 claims description 7
- 229910021645 metal ion Inorganic materials 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 208000031886 HIV Infections Diseases 0.000 claims description 6
- 208000037357 HIV infectious disease Diseases 0.000 claims description 6
- 108090001005 Interleukin-6 Proteins 0.000 claims description 6
- 102000004889 Interleukin-6 Human genes 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 102000010790 Interleukin-3 Receptors Human genes 0.000 claims description 5
- 108010038452 Interleukin-3 Receptors Proteins 0.000 claims description 5
- 102000004388 Interleukin-4 Human genes 0.000 claims description 5
- 108090000978 Interleukin-4 Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 4
- 230000016784 immunoglobulin production Effects 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 108010002616 Interleukin-5 Proteins 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 102000055276 human IL3 Human genes 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229940047122 interleukins Drugs 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100024819 Prolactin Human genes 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- 208000034615 apoptosis-related disease Diseases 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940097325 prolactin Drugs 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000002441 reversible effect Effects 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 7
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000000813 peptide hormone Substances 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 102000015731 Peptide Hormones Human genes 0.000 claims 1
- 108010038988 Peptide Hormones Proteins 0.000 claims 1
- 108010057464 Prolactin Proteins 0.000 claims 1
- 102100038803 Somatotropin Human genes 0.000 claims 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 108091005601 modified peptides Proteins 0.000 claims 1
- 108091005573 modified proteins Proteins 0.000 claims 1
- 230000009145 protein modification Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 6
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 abstract description 6
- 238000001415 gene therapy Methods 0.000 abstract description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 40
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 241000700605 Viruses Species 0.000 description 19
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 10
- 208000030507 AIDS Diseases 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 229940014800 succinic anhydride Drugs 0.000 description 10
- 101100069853 Caenorhabditis elegans hil-3 gene Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000011550 stock solution Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 102000018389 Exopeptidases Human genes 0.000 description 4
- 108010091443 Exopeptidases Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 4
- 108010002352 Interleukin-1 Proteins 0.000 description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 230000035322 succinylation Effects 0.000 description 4
- 238000010613 succinylation reaction Methods 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 3
- 102000008300 Mutant Proteins Human genes 0.000 description 3
- 108010021466 Mutant Proteins Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 102100039897 Interleukin-5 Human genes 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000000222 eosinocyte Anatomy 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 101150002378 gC gene Proteins 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000055277 human IL2 Human genes 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960005337 lysine hydrochloride Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 206010016228 Fasciitis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000687438 Homo sapiens Prolactin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000282620 Hylobates sp. Species 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 229940083963 Peptide antagonist Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100022563 Tubulin polymerization-promoting protein Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010317 ablation therapy Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- AAAQZCQXXCUUCV-UHFFFAOYSA-N acetyl acetate;oxolane-2,5-dione Chemical compound CC(=O)OC(C)=O.O=C1CCC(=O)O1 AAAQZCQXXCUUCV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 238000002011 beta-particle spectroscopy Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 201000001561 eosinophilic gastritis Diseases 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 210000004186 follicle cell Anatomy 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057308 human HGF Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940076372 protein antagonist Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention is on the area of the chemical modification technology of biologically active proteins and peptides. More specifically it concerns use of chemical modification to obtain a protein or peptide with superior properties or with new or even counteracting properties. In addition, the invention also concerns a new method for structure-function analysis by using gradual chemical modification, a biological principle, namely the catalytic activity of signal peptides and the successful abrogation thereof, leading to a very effective inhibitor of Acute Myeloid Leukemia cells.
- a field for an IL-3 with superior properties (Superagonist) or a field for an IL-3 with counteracting or new properties (Antagonist).
- Superagonists are for instance an IL-3 with a lowered antigenecity and/or a higher biological activity and/or a higher stability.
- Possible applications of IL-3 Superagonists are: reduction of the cytopenic phase after myelo-ablative therapy like after inductive therapy for bone marrow transplantation or after accidental radiation, induction of a synchronized cell-cycle of cells with an IL-3 receptor, for instance for chemotherapy of leukemia's.
- Some, but not all, examples of applications of signal-substance antagonists (with counteracting or cell-inhibitory activity), more specifically of IL-3 are: inhibition and/or neutralization of myeloid cells in bone marrow transplantation. myelo-suppression in auto immune-diseases, cancer and diseases of the blood forming organs, like sickle cell anemia and thallisemia. treatments to cure all sorts of cancer that involve cells with the IL-3 receptor, more specifically almost all forms of acute myeloid leukemia or chronic myeloid leukemia, B-cell lymphoid tumors or other forms of cancer that are stimulated by
- IL-3 for instance certain follicle cell tumors.
- This can also lead to the impaired generation and elimination of effector cells like the eosinophilic granulocyte.
- effector cells like the eosinophilic granulocyte.
- there is a direct interaction with these cells thus enabling a direct cure of the eosinophilic syndrome. This is also of great importance in acute phases of worm infections and hypersensitivity reactions to for instance medicinal drugs.
- eosinophilic syndromes like eosinophilic gastritis and enteritis, fascitis, granulomatosis, sinusitis, pneumonia, asthma, Churg Strauss syndrome and other angitis treatments of the shock syndrome for instance by killing or suppressing the number of effector cells.
- ablation or suppression of cells with an IL-3 receptor like lymphoid cells and/or effector cells like the eosinophilic granulocyte, for the treatment of allergies. In these cases both suppression of the allergy and induction of tolerance towards the antigen are possible.
- other allergic reactions where the action of IL-3 is involved.
- treatments to prevent metastases that are stimulated by IL-3 mediated adhesion treatment of infectious diseases, for instance by suppressing an acute phase where there is an occurrence of excessive amounts of growth factor in the blood stream.
- IL-4 inhibition to suppress IL-4 stimulated viruses like for instance the radiation leukemia virus in mice.
- Antibodies can protect HIV and/or HIV-infeeted cells against cellular immunity. This explains the defective overall resistance in the asymtomatic phase of the HIV infection in spite of very high levels of in vitro neutralizing antibodies and a demonstrated cellular resistance. As demonstrated in the example the lowering of the antibody-levels can result in an effective cellular immunity against the virus and the virus infected cells and even the elimination of the virus. Therefore, the inhibition of B-cells with for instance antagonists can lead to a cure of the HIV infection.
- the modified signal peptides can also be generated by molecular biology
- these mutant proteins, DNA-constructs and the use thereof are also considered to be within the scope of the invention.
- the use in gene- therapy can result in cells that are producing and excreting the super-agonist or the antagonist. Therefore, in one of the examples there is also an elaboration on the possibility to construct a growth factor with a reduced stability. This can be used especially in combination with antagonistic action, thus resulting in a selective administration whereby the high rate of breakdown of the antagonist can contain the action to a very localized environment. This is particularly interesting in gene-therapy for solid tumors.
- the description of the invention also discloses the importance of metal ions with more than 1 valence in charge, by preference Zinc-ions, especially for catalytic activity and the subsequent efficacy. Therefore, it is possible to influence the growth factor action by manipulating the (local) metal ions concentrations. Since there is a usual optimum in efficacy of the metal ions concentration, and any concentration below or beyond this optimum can lead to reduction of efficacy of the growth factor. This enables manipulation of the efficacy of the growth factor. In this way also indirect therapeutic effects can be achieved with metal-, preferably Zinc ions. This can be used in treatment of skin-diseases like wrath's in the form of ointments. Also, the use of inhalation-sprays for treatment of lung-affects is possible.
- Interleukin-3 which was first isolated from T-cells as a glycoprotein, has been demonstrated to act on bone-marrow cells. Either with or without other growth factors it has been shown to induce the formation of various blood cells from these bone-marrow cells.
- Human LL-3 has been cloned for the first time in 1987 by Dorssers et al. who used a human c-DNA library and hybridization with a probe of mouse DNA ( Gene 55: 1 15 (1987).
- deletion mutants In their research they all used molecular biological techniques like the generation of deletion and substitution mutants. In the case that substitution mutants were used, the choice was based on the amino-acid homology ofIL-3 with other species (mouse, rhesus monkey, gibbon) or it was based on deliberate changes of polarity or structure. With deletion mutants the protein was scanned for biological importance by removal of parts of the protein. Because of practical problems with regard to purification of the mutant- proteins(muteins) these mutant proteins have never been checked for major structural changes. This is a major problem since these structural changes usually do occur. As described, sometimes they are even deliberately introduced. As a result any statement regarding the involvement of various amino acids on the biological activity can only be made with the greatest reservations.
- the starting material can be any protein or peptide containing substance.
- the Zinc ions can protect against denaturation, it might be necessary to reversibly denaturate the molecule and to add chelating agents to remove this Zinc from the molecule.
- the modification of IL-3 with Iodo-acetate is described. At the concerning pH this modification is directed to alkylation of His-residues.
- the method can be performed easily also with other reagents by a person that is skilled in the art.
- the same can be stated about the modification of other amino acids that are involved in the catalytic activity and/or Zinc binding.
- these residues can be easily modified by other chemical ways or by molecular biological ways, for instance by using deletion or substitution mutations.
- IL-3 In addition this is not limited to IL-3 alone: There is a significant homology among the various receptors of the cytokine-superfamily: For instance Interleukins 2-7 Epo and GM-CSF. On top of that specific Zinc binding has also been found for IL-2 IL-6 GM-CSF and gamma IFN. It is also conceivable that the invention can be applied to much more signal peptides and/or proteins, since for instance Insulin, human growth hormone and prolactin also have specific Zinc binding properties. In addition, it has been found that for certain cell-lines IL-3 can be replaced by for instance Insulin. Finally it is possible that alkylation of a growth factor also has an other mechanism in the generation of a antagonist or cell-inhibitor.
- the invention can possibly be applied to the fight against ADDS. It should provide a better way to combat AIDS than the current possibilities:
- CD4 positive cells will be infected by the HIV after a short time.
- our invention leads to the effective cellular immune-response against retroviruses.
- HIV gly ⁇ oprotein 160/120 complex are generated.
- this approach lead to the protection of the HIV and its integration in histiocytic cells, thereby even promoting the disease. As a result the method could not demonstrate efficacy.
- Vaccines that are based on inactivated viruses combine the objections of the two aforementioned patents.
- HTLV ⁇ IB AIDS Research and Reference Reagent Program Catalog, NIH Publication No. 91- 1536, Bethesda, MD, USA
- HTLV ⁇ IB AIDS Research and Reference Reagent Program Catalog, NIH Publication No. 91- 1536, Bethesda, MD, USA
- these viruses can be eliminated if the antibody levels are low.
- B-cells and the subsequent antibody production by these B-cells is stimulated by various growth factors (for instance IL-1 -7 and IL-1 1). Therefore it is logical that the therapy against AIDS can also be accomplished by using antagonists of these growth factors. Thus, also the treatment of AIDS is considered to be one of the applications of the invention.
- Acetic Acid, dioxane, lysine hydrochloride and MES were from Sigma, the modifying agent was from Fluka.
- Buffers Acetate/NaOH was used for modification at pH 5.0, MES/NaOH was used for modification at pH 5.5, 6.0 and 6.5. At pH 7.0 an NaH2PO4 / NaOH buffer was used.
- the reaction mixture contained 50 mM buffer, 2 mg/ml hLL-3 and 3 mM Acetic anhydride or Succinic anhydride respectively.
- the 10 times concentrated stock solutions were prepared fresh at the day of the experiment. Modification of hIL-3 was performed overnight at 30 °C. After modification it was determined by SDS-electrophoresis that the
- MO-7 cells were a kind gift of dr. I.P. Touw (Erasmus University of Rotterdam, The Netherlands).
- RPMI culture medium was from Gibco (Paisly, UK.), supplemented Bovine Calf Serum was from Hyclone (Logan, Utah, USA.)
- the cell culture medium consisted of RPMI with 10 % of the calf serum. During normal tissue culture of the cells also 100 ng ml LL-3 was added. 10
- the relative activity of the modified substances was determined as the ratio of these 50 % concentrations of the modified and the native IL-3 respectively ( [IL-3 m odified] 50% / [LL-3native] 50% )•
- Table 1 Relative biological activities of acetylated IL-3.
- Example 2 From the table it can be concluded that there is a significant difference in relative activity between day 6 and day 10 after modification at pH 6.5 and pH 7.0. Therefore, it can be assumed that this demonstrates the generation of a substance with significantly lowered stability. At pH 5 there might be an enhancement of biologic activity. Further aspects are discussed in examples 5 and 6.
- Example 2 Example 2:
- Acetic Acid, dioxane, lysine hydrochloride and MES were from Sigma, the modifying agent was from Fluka.
- Buffers Acetate/NaOH was used for modification at pH 5.0, MES/NaOH was used for modification at pH 5.5, 6.0 and 6.5. At pH 7.0 an NaH2PO . / NaOH buffer was used.
- the reaction mixture contained 50 mM buffer, 2 mg/ml hLL-3 and 3 mM Acetic anhydride or Succinic anhydride respectively.
- the 10 times concentrated stock solutions were prepared fresh at the day of the experiment. Modification of hIL-3 was performed overnight at 30 °C. After modification it was determined by SDS-electrophoresis that the
- a method to chemically modify biologically active peptides or proteins for the generation of a protein or peptide antagonist is a method to chemically modify biologically active peptides or proteins for the generation of a protein or peptide antagonist.
- Urea, EDTA, MES and NaOH were from Sigma, the Na-Iodo-acetate was from Fluka. Buffers: MES/NaOH was used for modification at pH 6.0. Ten times concentrated stock solutions were prepared in 8 M urea and filter-sterilized directly thereafter with a 0.22 micron filter. The reaction mixture contained 50 mM buffer, 5.5 M urea and 50 mM EDTA. From these reagents 10 times concentrated stock solutions in 8 M urea were made freshly on the day of the experiment.
- Iodo-acetate was added in a concentration of 3, 10 and 30 mM.
- the IL-3 concentration was 2 mg/ml.
- the modification was performed during 24, 48 and 72 hours at 37 °C and subsequently it was studied by native electrophoresis. After 2 days and 30 mM Iodo- acetate there was maximal modification without severe distortion of the bands from the modified material (an indication of severe denaturation of the molecules). In this case less than 2 % of the starting material was left. Because in this case there was an expectation of a minimal biological activity without severe denaturation of the protein, this sample was used in further experiments. Subsequently, SDS electrophoresis was used to demonstrate that no degradation of the molecule was found after modification.
- the modified IL-3 is capable to inhibit the control-IL-3 by a factor 10-100.
- 3 ng/ml of the modified IL-3 is able to suppress thymidine incorporation of 30- 100 ng/ml control IL-3 for 80-90 %. Therefore, the modified IL-3 does not only have an Inhibitory activity, it also has an enhanced receptor binding capacity. This is confirmed in the titration of partially modified IL-3 (figure 2): Only 0.1 ng of partially modified IL-3 is sufficient for almost 50 % inhibition of 3 ng/ ml native IL-3.
- Cathepsine-C was added in serial two fold dilution's in a range of 1/2 to 1/128 mg/ml. The other reaction conditions were as described by the manufacturer.
- Protease treatment Average relative activity ( and range) in tissue culture
- Cathepsine C significantly enhances the activity at day 6 but not at day 10. Therefore, this is a also substance with a lowered stability.
- Protease treatment For localization of the modified residues the modified material was dialyzed against the appropriate buffer and subsequently fragmented by Endo Glu-C or Endo Lys-C as described by the manufacturer (Boehringer Mannheim, Germany). The incubation was overnight at 37 °C, 2 mg/ml hIL-3 and a protein to protease ratio of 30.
- Matrix Assisted Laser Desorption mass spectrometry was performed on a Finnegan MAT Vision 200 laser desorption mass spectrometer, equipped with a pulsed nitrogen laser (337 nm, pulse width 3 ns). The sample was exited to just above the ionization threshold (10 6 -10 7 W/cm 2 ). The acceleration voltage was 6.5 kV. The ions were post accelerated to the conversion dynode on - 10 kV for the electron amplification. Standard accuracy was about 0.05 %, but this can deteriorate to 0.1-0.2 % due to experimental conditions.
- Lys 116 ⁇ 40% Lys 116 ⁇ 40%
- the second step is the monitoring of the modification reaction.
- a mild and sensitive method is needed. This method is native electrophoresis (Electrophoresis 15: 251 (1994)).
- electrospray mass spectrometry can form a suitable alternative. This is demonstrated in figure 3: Electrospray Mass Spectrometry of Succinylated IL-3 at pH 5-7. Especially the combination of both enables the demonstration of complete specificity on amine-residues.
- the third step is the confirmation of the overall structural integrity.
- Circular Dichroism Spectroscopy can be used for this purpose(Electrophoresis 15: 251 ( 1994)). Although small differences are not visible by this method, substantial structural changes like denaturation are clearly detected.
- the fourth step is the characterization and localization of the modified residues, for which the following techniques were used: native digestion with specific protease's, electrophoresis, electrospray mass spectrometry, and LDMS.
- native digestion with specific protease's native digestion with specific protease's
- electrophoresis electrophoresis
- electrospray mass spectrometry and LDMS.
- the reaction specificity was determined by the combination of native electrophoresis and electrospray mass spectrometiy. Localization was performed with endoprotease's and LDMS, as described in the previous example.
- the fifth and last step is the testing of biological activity of the various modified forms of the protein. After this determination of activity the real involvement of the various localized residues can be deduced.
- Lys 1 16 and the amino-terminus are of biological significance, while the amino terminus seems to have an inhibitory or regulating influence, Lys 1 16 seems to be important for the biological activity.
- Lys 1 16 is also protected by phosphate, suggesting a phosphate binding by that residue. Since the residue is also important for the biological activity of the interleukin, this suggests that phosphate-binding is of importance for the mode of action of IL-3 and if this process is of importance for IL-3, it can also be of importance for other peptides and proteins.
- this method enables the localization of biologically important residues and the demonstrated phosphate binding has also enabled the establishment and localization of a possibly important physiological process. Therefore, the invention also embodies the modification of a protein or peptide to introduce a new, preferably antagonistic activity by means of the manipulation of the phosphate binding of the protein or peptide.
- the test system consisted of human chimeric 4 week old "X-linked immunodeficient" Mice .
- the chimerism was induced with conditioning by total body irradiation (TBI), and transplantation of 4 million human peripheral blood lymphocytes / gram of recipient.
- TBI total body irradiation
- the TBI of the CBA N mice was 9 Gy gamma.
- These mice also received a blood supporting treatment in the form of 0.5 million autologous bone-marrow cells intravenously (iv). Comparable irradiation, processing of the human blood and the transplantation is described in the Eur. J. Immunol. 22: 197 (1992).
- the mice were injected intraperitoneally (ip) daily with 10.000 LU.
- the conditioned CBA/N mice were pretreated ip with 250 microgram of monoclonal antibody anti- HIV-1 GP13 (against the CD4-binding place) or the anti HTLVI ⁇ B F58H3 directed at the V3-I00P.
- the ICT was performed in duplo with CB 15 cells (Proc. Natl. Acad. Sci. USA. 89: 31 16 (1992)). Ten thousand cells were plated per well and after 5-7 days an ELISA was performed on HIV p24 protein (Organon Technica, Oss, The Netherlands). The sacrifice of the animal was always within 2 weeks after transplantation thus eloping the production of antibodies (unpublished data). On the day of the sacrifice of the mice, the cells were rinsed from the peritoneal cavity with medium that contained heparin (Organon Technica, Oss, The Netherlands). On these cells the ICT was performed in presence of CB 15 cells and 100 I.U. human Interleukin-2 / ml of culture medium.
- HTLV ⁇ IB persists for the first 5 days under these circumstances. However 8 days after the transplantation it appears to have been eliminated, even in abundant presence of human CD4 + cells. This indicates that the transplanted human T- cells eliminate the virus. However if either of the specific anti-HIV-1 antibodies are administered to the chimeric mice, the virus did persist (Table 5), demonstrating that the persistence of HIV-infection is caused by antibodies.
- Plasmaphoresis that results in the lowering of the antibody-level.
- the usual clinical practice is the complete substitution of the plasma.
- An experimental therapy for instance for myasthenia gravis is the so called selective recovery of the plasma.
- the plasma of the patient is purified from the harmful antibodies before returning to the patient.
- This in vitro selection can also be used for HTV-reactive, by preference HTV-envelope reactive antibodies.
- Leukophoresis for the lowering of the number of B-cells. It is preferred to remove the B- cells that are HIV -reactive. The leukocytes can be removed totally from the HIV-infected person. This form of leukophoresis is a routine clinical practice for other diseases. For HIV infected persons however, it has never been described. Alternatively the selective return of the white blood cells without B- cells can very easily be done. Selection can also consist of positive selection for T-cells or sub populations thereof.
- the invention also includes in vivo depletion by formation of immune complexes, as well selective as non-selective.
- Non selective removal is preferably done by antibody-specific antibodies.
- Selective removal is preferably done by virus, inactivated virus, virus-subunits and/or virus-like or identical proteins or peptides. These substances are preferably coupled to substances that promote clearing from the body.
- B-cells In vivo depletion of B-cells. This in vivo depletion can be performed trough non-selective removal with B-cell specific antibodies, by preference with B-cell apoptose-inducing antibodies. This can also be performed with bi-specific antibodies, preferably of the combination CD19/CD3-reactivity. This has already been used in a phase 1 clinical trial in the Academic Hospital Utrecht (Utrecht, The Netherlands) for patients with B-cell tumors. This therapy results in a very substantial depletion of the number of B-cells (Personal communication: F.A. van Houten Academic Hospital Utrecht, The Netherlands). Selective removal of B- cells is preferably done by virus, inactivated virus, virus-subunits and/or virus ⁇ like or identical proteins or peptides or by antibodies. Preferably, these substances are coupled to B-cell depletion promoting substances.
- TGF-beta transforming growth factor beta
- HIV and other viruses integrate as provirus in the host genome. Therefore it can be present in these cells in al latent state for a long time. Therefore, in this invention it is preferred to activate such a provirus, preferably by administration of IL-2 to the host.
- HIV persists in the histiocytic cells and these can produce low concentrations of virus that might escape recognition by the hosts immune-system. Therefore it is preferred to prolong the treatment for at least the life-time of these cells.
- passive immune-therapy preferably with immunoglobulins of subjects that are not HIV-infected. Therefore, this passive immune therapy is to be considered within the scope of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU32668/95A AU3266895A (en) | 1994-08-31 | 1995-08-30 | Gradual modification, super-agonists and antagonists of sinal-proteins and peptides |
JP8508637A JPH10507161A (en) | 1994-08-31 | 1995-08-30 | Stepwise modification of signal proteins and signal peptides and super agonists and antagonists |
EP95929258A EP0796276B1 (en) | 1994-08-31 | 1995-08-30 | Gradual modification, super-agonists and antagonists of signal-proteins and peptides |
DE69531955T DE69531955T2 (en) | 1994-08-31 | 1995-08-30 | PROGRESSIVE CHANGE OF SIGNAL PROTEINS AND PEPTIDES AND THE PRODUCED SUPERAGONISTS AND ANTAGONISTS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL9401404A NL9401404A (en) | 1994-08-31 | 1994-08-31 | Gradual chemical modification of biologically active peptides and proteins |
NL9401404 | 1994-08-31 | ||
NL1000332A NL1000332C1 (en) | 1994-08-31 | 1995-05-10 | Gradual chemical modification of biologically active peptides and proteins. |
NL1000332 | 1995-05-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996006860A2 true WO1996006860A2 (en) | 1996-03-07 |
WO1996006860A3 WO1996006860A3 (en) | 1996-07-18 |
Family
ID=26642070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NL1995/000292 WO1996006860A2 (en) | 1994-08-31 | 1995-08-30 | Gradual modification, super-agonists and antagonists of signal-proteins and peptides |
Country Status (9)
Country | Link |
---|---|
US (1) | US20020150551A1 (en) |
EP (1) | EP0796276B1 (en) |
JP (1) | JPH10507161A (en) |
AU (1) | AU3266895A (en) |
CA (1) | CA2198919A1 (en) |
DE (1) | DE69531955T2 (en) |
ES (1) | ES2208691T3 (en) |
NL (1) | NL1000332C1 (en) |
WO (1) | WO1996006860A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000049040A2 (en) * | 1999-02-05 | 2000-08-24 | Endogen Research Ph Ab | Antimicrobial/endotoxin neutralizing polypeptide |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007070392A2 (en) * | 2005-12-12 | 2007-06-21 | Canji, Inc. | Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005824A1 (en) * | 1987-12-23 | 1989-06-29 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides to facilitate covalent linkages to a hydrophilic moiety |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4511502A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
EP0279846A1 (en) * | 1986-09-04 | 1988-08-31 | Cetus Corporation | Succinylated interleukin-2 for pharmaceutical compositions |
AU5670994A (en) * | 1992-11-24 | 1994-06-22 | G.D. Searle & Co. | Interleukin-3 (il-3) mutant polypeptides |
US5501962A (en) * | 1993-06-21 | 1996-03-26 | G. D. Searle & Co. | Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same |
US5658739A (en) * | 1994-05-10 | 1997-08-19 | The Regents Of The University Of California | Method for characterization of the fine structure of protein binding sites |
US5710252A (en) * | 1995-02-03 | 1998-01-20 | Eastman Kodak Company | Method for recombinant yeast expression and isolation of water-soluble collagen-type polypeptides |
-
1995
- 1995-05-10 NL NL1000332A patent/NL1000332C1/en not_active IP Right Cessation
- 1995-08-30 CA CA002198919A patent/CA2198919A1/en not_active Abandoned
- 1995-08-30 AU AU32668/95A patent/AU3266895A/en not_active Abandoned
- 1995-08-30 ES ES95929258T patent/ES2208691T3/en not_active Expired - Lifetime
- 1995-08-30 EP EP95929258A patent/EP0796276B1/en not_active Expired - Lifetime
- 1995-08-30 US US08/807,506 patent/US20020150551A1/en not_active Abandoned
- 1995-08-30 DE DE69531955T patent/DE69531955T2/en not_active Expired - Lifetime
- 1995-08-30 WO PCT/NL1995/000292 patent/WO1996006860A2/en active IP Right Grant
- 1995-08-30 JP JP8508637A patent/JPH10507161A/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989005824A1 (en) * | 1987-12-23 | 1989-06-29 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides to facilitate covalent linkages to a hydrophilic moiety |
Non-Patent Citations (4)
Title |
---|
ELECTROPHORESIS, vol.15, no.2, , WEINHEIM pages 251 - 254 V.SMIT 'Native electrophoresis to monitor chemical modifications of human Il-3' * |
JOURNAL OF BIOLOGICAL CHEMISTRY, vol.266, no.16, 5 June 1991, MD US pages 10624 - 10631 N.A.LOKKER ET AL 'Structure-activity relationship study of hIL-3' cited in the application * |
L.STRYER 'biochemistry' , FREEMAN , NEW YORK see page 162; figures 7-38 * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol.89, 2, WASHINGTON US pages 11842 - 11846 A.F.LOPEZ ET AL 'A hIL-3 analog with increased biological and binding activities' cited in the application * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
US7105653B2 (en) | 1998-05-15 | 2006-09-12 | Shanafelt Armen B | IL-2 selective agonists and antagonists |
WO2000049040A2 (en) * | 1999-02-05 | 2000-08-24 | Endogen Research Ph Ab | Antimicrobial/endotoxin neutralizing polypeptide |
WO2000049040A3 (en) * | 1999-02-05 | 2000-12-14 | Endogen Res Ph Ab | Antimicrobial/endotoxin neutralizing polypeptide |
US6399570B1 (en) | 1999-02-05 | 2002-06-04 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
US7244706B2 (en) | 1999-02-05 | 2007-07-17 | Agennix, Inc. | Antimicrobial/endotoxin neutralizing polypeptide |
Also Published As
Publication number | Publication date |
---|---|
JPH10507161A (en) | 1998-07-14 |
EP0796276A1 (en) | 1997-09-24 |
NL1000332C1 (en) | 1996-03-04 |
AU3266895A (en) | 1996-03-22 |
WO1996006860A3 (en) | 1996-07-18 |
US20020150551A1 (en) | 2002-10-17 |
EP0796276B1 (en) | 2003-10-15 |
DE69531955D1 (en) | 2003-11-20 |
ES2208691T3 (en) | 2004-06-16 |
DE69531955T2 (en) | 2004-07-29 |
CA2198919A1 (en) | 1996-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100607609B1 (en) | IL-2 Selective Agonists And Antagonists | |
AU651152B2 (en) | Multidomain hematopoiesis stimulators | |
JP3261124B2 (en) | Natural killer cell stimulating factor | |
US20040175357A1 (en) | IL-2 selective agonists and antagonists | |
RO117110B1 (en) | Mpl LIGAND POLYPEPTIDE, NUCLEIC ACID ENCODING THE SAME, EXPRESSION VECTOR, PROCESS FOR PRODUCING THE LIGAND POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION | |
KR20170094341A (en) | Interleukin 15 protein complex and use thereof | |
KR20020018197A (en) | EXPRESSION AND EXPORT OF INTERFERON-ALPHA PROTEINS AS Fc FUSION PROTEINS | |
JPH10503371A (en) | New compound | |
CZ414191A3 (en) | Human interleukin-4 | |
US20070299026A1 (en) | Immunosuppressive Cytokine | |
AU2001292645A1 (en) | Modulation of IL-2- and IL-15-mediated T cell responses | |
CA2212006A1 (en) | Novel c-mpl ligands | |
AU1533597A (en) | Novel administration of thrombopoietin | |
US20020150551A1 (en) | Gradual modification, super-agonists and antagonists of signal - proteins and peptides | |
AU2003248017B2 (en) | Gradual modification super-agonists and antagonists of signal-proteins and peptides | |
AU762023B2 (en) | Gradual modification, super-agonists and antagonists of signal-proteins and peptides | |
AU2007200889A1 (en) | Gradual modification super-agonists and antagonists of signal-proteins and peptides | |
WO2000009150A2 (en) | Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use | |
WO2023053315A1 (en) | Pd-1 expression inhibitor, pharmaceutical composition for immune checkpoint inhibition, and method for inhibiting pd-1 expression | |
CN1163620A (en) | Gradual modification super-agonists and antagonists of signal-proteins and peptides | |
MXPA06001037A (en) | A method of improving efficacy of biological response-modifying proteins and the exemplary muteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194849.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995929258 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08807506 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2198919 Country of ref document: CA Ref document number: 2198919 Country of ref document: CA Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1995929258 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995929258 Country of ref document: EP |